Cefazolin (sodium salt)
(Synonyms: 头孢唑林钠; Cephazolin sodium) 目录号 : GC10179
A cephalosporin antibiotic
Cas No.:27164-46-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cefazolin is a semisynthetic antibiotic with a broad spectrum of antibacterial activity. Cefazolin has exhibited high activity against Gram-positive bacteria and Gram-negative bacteria [1].
In vitro: In cultured MG-63 human osteosarcoma cell line, cefazolin (100 μg/ml) showed little or no effect on osteoblast replication. Cefazolin (200μg/ml) significantly decreased cell replication, and 10,000 μg/ml caused cell death [2].
In vivo: In patients with normal and various degrees of compromised renal function, administration of cefazolin significantly decreased the urinary concentration and percentage of the dose excreted in the urine [3]. The half-life of cefazolin in serum of normal persons was 1.9 hr and as long as 35 hr in severely uremic patients. In uremic patients, cefazolin was well tolerated [4].
References:
[1] Kariyone K, HARADA H, KURITA M, et al. Cefazolin, a new semisynthetic cephalosporin antibiotic. I[J]. The Journal of antibiotics, 1970, 23(3): 131-136.
[2] Edin M L, Miclau T, Lester G E, et al. Effect of cefazolin and vancomycin on osteoblasts in vitro[J]. Clinical orthopaedics and related research, 1996, 333: 245-251.
[3] Levison M E, Levison S P, Ries K, et al. Pharmacology of cefazolin in patients with normal and abnormal renal function[J]. Journal of Infectious Diseases, 1973, 128(Supplement 2): S354-S357.
[4] Craig W A, Welling P G, Jackson T C, et al. Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency[J]. Journal of Infectious Diseases, 1973, 128(Supplement 2): S347-S353.
| Cas No. | 27164-46-1 | SDF | |
| 别名 | 头孢唑林钠; Cephazolin sodium | ||
| 化学名 | (6R)-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7R-[[2-(1H-tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt | ||
| Canonical SMILES | O=C(CN1N=NN=C1)N[C@H](C2=O)[C@]3([H])N2C(C([O-])=O)=C(CSC4=NN=C(C)S4)CS3.[Na+] | ||
| 分子式 | C14H13N8O4S3 • Na | 分子量 | 476.5 |
| 溶解度 | ≥ 25.5mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0986 mL | 10.4932 mL | 20.9864 mL |
| 5 mM | 0.4197 mL | 2.0986 mL | 4.1973 mL |
| 10 mM | 0.2099 mL | 1.0493 mL | 2.0986 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet